Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Advanced Biomedical Research and Innovation
betkolik betlike betpark betticket betturkey extrabet holiganbet ilbet ikimisli imajbet jojobet kralbet mariobet marsbahis meritking milanobet piabet redwin süpertotobet tempobet
Guoxuan Sun Author
Subjects of specialization
Affiliation
Applied Microbiology, Applied Microscopy, Applied Mycology, Applied Physiology, Biomedical Research
skilled in chemical synthesis University College London, UK ,
Biography
A PhD majoring drug discovery in UCL school of pharmacy. My project aims to develop a Novobiocin based anti-cancer drug candidate, targetting human Heat shock protein 90. I am skilled in chemical synthesis, protein target validation and HPLC. Have experience in structural biology, proteomics analysis, mass spec analysis, protein biology and analytical chemistry.
Publications
Short Communication Open Access
Application of targetted covalent drug design method towards the design of Hsp90 CTD covalent inhibitors
Author(s): Guoxuan Sun, Francisco Humberto Xavier Junior, Banghao Yuan, Andreas Schatzlein and Stephen Hilton
Hsp90 (Heat shock protein 90) is an inductive molecular chaperone that governs the correct protein folding to resist environmental stress. It has been a promising anti-cancer drug target significantly overexpressed by cancer cells (up to 55.6%). However, currently, there is no approved drug of this type due to the high toxicity and harmful heat shock response found in Hsp90 NTD (N-terminus domain) inhibitors. In recent decades, the Hsp90 CTD (C-terminus domain) inhibitor is an excellent alternative to Hsp90 NTD inhibitors, triggering no heat shock response. Nevertheless, the lack of a drug-protein co-crystal structure limited its development and created a gap between detailed structural activity data and clinical trials. There is no Hsp90 CTD inhibitor has entered any clinal trials due ... view more»
Google Scholars / Researchers Sites
